CN102791294A - 用于多种药物递送的粒子 - Google Patents

用于多种药物递送的粒子 Download PDF

Info

Publication number
CN102791294A
CN102791294A CN2010800640099A CN201080064009A CN102791294A CN 102791294 A CN102791294 A CN 102791294A CN 2010800640099 A CN2010800640099 A CN 2010800640099A CN 201080064009 A CN201080064009 A CN 201080064009A CN 102791294 A CN102791294 A CN 102791294A
Authority
CN
China
Prior art keywords
particle
activating agent
particles
polymer
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800640099A
Other languages
English (en)
Chinese (zh)
Inventor
O.C.法罗克扎德
N.科利施蒂
S.达尔
S.J.利帕德
R.S.兰格
P.M.瓦伦西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Massachusetts Institute of Technology
Original Assignee
Brigham and Womens Hospital Inc
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Massachusetts Institute of Technology filed Critical Brigham and Womens Hospital Inc
Publication of CN102791294A publication Critical patent/CN102791294A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800640099A 2009-12-16 2010-12-16 用于多种药物递送的粒子 Pending CN102791294A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28718809P 2009-12-16 2009-12-16
US61/287,188 2009-12-16
PCT/US2010/060814 WO2011084620A2 (en) 2009-12-16 2010-12-16 Particles for multiple agent delivery

Publications (1)

Publication Number Publication Date
CN102791294A true CN102791294A (zh) 2012-11-21

Family

ID=44306061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800640099A Pending CN102791294A (zh) 2009-12-16 2010-12-16 用于多种药物递送的粒子

Country Status (7)

Country Link
US (1) US20130017265A1 (https=)
EP (1) EP2512522A4 (https=)
JP (1) JP2013514977A (https=)
CN (1) CN102791294A (https=)
EA (1) EA201290506A1 (https=)
IN (1) IN2012DN05099A (https=)
WO (1) WO2011084620A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659797A (zh) * 2014-05-29 2017-05-10 纪念斯隆-凯特琳癌症中心 纳米粒子药物结合物
CN114259573A (zh) * 2022-01-06 2022-04-01 中国人民解放军军事科学院军事医学研究院 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途
CN115382476A (zh) * 2022-07-26 2022-11-25 华东师范大学 一种超小粒径聚合物纳米颗粒的制备方法
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003109A1 (en) 2009-07-02 2011-01-06 Sloan-Kettering Institute For Cancer Research Fluorescent silica-based nanoparticles
US20130202712A1 (en) * 2010-03-02 2013-08-08 Vindico Nanobio Technology, Inc. Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2013033513A1 (en) * 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
EP2812313A4 (en) 2012-02-09 2015-09-30 Novus Int Inc FUNCTIONALIZED POLYMERIC COMPOSITIONS
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
MX2015000395A (es) 2012-07-12 2015-04-10 Novus Int Inc Composiciones de matriz y capa para proteccion de bioactivos.
JP2014051478A (ja) * 2012-09-10 2014-03-20 Panasonic Corp 機能性物質、生体活性用薬剤及び機能性物質の生体内への浸透方法、並びに機能性物質放散装置及び空気清浄装置
WO2014059022A1 (en) 2012-10-09 2014-04-17 The Brigham And Women's Hospital, Inc. Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
US20160279263A1 (en) * 2012-11-14 2016-09-29 Cornell University Drug delivery compositions and methods targeting p-glycoprotein
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
EP2968621B1 (en) 2013-03-15 2022-08-10 Memorial Sloan-Kettering Cancer Center Multimodal silica-based nanoparticles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014169007A2 (en) * 2013-04-09 2014-10-16 University Of Georgia Research Foundation Inc. Combination therapeutic nanoparticles
US9802984B2 (en) 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
US10004809B2 (en) 2013-07-01 2018-06-26 University Of Georgia Research Foundation Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
CA2918541A1 (en) * 2013-07-26 2015-01-29 The University Of British Columbia Method and device for manufacturing polymer particles containing a therapeutic material
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US20170190726A9 (en) * 2013-12-12 2017-07-06 University Of Georgia Research Foundation, Inc. Prodrug for release of cisplatin and cyclooxygenase inhibitor
JP6681334B2 (ja) 2013-12-31 2020-04-15 メモリアル スローン ケタリング キャンサー センター リアルタイムの蛍光源のマルチチャネル撮像のためのシステム、方法、および装置
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3129017A4 (en) * 2014-04-08 2017-11-08 University of Georgia Research Foundation, Inc. Mitochondria-targeting platinum(iv) prodrug
MX2017003903A (es) 2014-10-03 2017-09-15 Ntercept Llc Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
JP6974178B2 (ja) 2015-05-29 2021-12-01 メモリアル スローン ケタリング キャンサー センター フェロトーシスを介して栄養欠乏がん細胞の細胞死を誘導するための極小ナノ粒子を使用する処置方法
CA2989001A1 (en) * 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
EP3334460A4 (en) * 2015-08-13 2019-04-03 Northeastern University BIOMATERIALS FOR COMBINED RADIOTHERAPY AND IMMUNOTHERAPY OF CANCER
EP3377113A4 (en) * 2015-11-18 2019-06-19 Synergy Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF TREATMENT AND DETECTION OF CANCER
CA3009186A1 (en) * 2015-12-23 2017-06-29 Dana-Farber Cancer Institute, Inc. Immune cell-targeted particles
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
CA3064253A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
US20240293600A1 (en) * 2021-06-21 2024-09-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods, and devices for sustained release of an agent
WO2025240771A1 (en) * 2024-05-16 2025-11-20 Curadel Surgical Innovations, Inc. Small zwitterionic multimeric targeted drugs and methods of use and manufacture thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322805B1 (en) * 1995-09-21 2001-11-27 Samyang Corporation Biodegradable polymeric micelle-type drug composition and method for the preparation thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ATE317690T1 (de) * 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2001047501A1 (en) * 1999-12-29 2001-07-05 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
DE60140625D1 (de) * 2000-08-15 2010-01-07 Univ Illinois Verfahren zur herstellung von mikropartikeln
US7125546B2 (en) * 2000-09-26 2006-10-24 Toudai Tlo, Ltd. Polymeric micelle containing cisplatin enclosed therein and use thereof
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7371781B2 (en) * 2003-09-22 2008-05-13 University Of Utah Research Foundation Tumor environment-induced ligand-expressing nanocarrier system
AU2003272127A1 (en) * 2003-10-24 2005-05-11 Samyang Corporation Polymeric composition for drug delivery
WO2006078282A2 (en) * 2004-04-28 2006-07-27 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
JP2008506780A (ja) * 2004-07-19 2008-03-06 セレーター ファーマスーティカルズ、インク． 活性剤放出のための粒子状構築物
IL178645A0 (en) * 2006-10-16 2007-02-11 Ariel University Res And Dev C Dendrimeric platform for controlled release of drugs
CN101679021B (zh) * 2007-03-02 2014-04-30 伊利诺伊大学评议会 药物颗粒送递
US20080279778A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322805B1 (en) * 1995-09-21 2001-11-27 Samyang Corporation Biodegradable polymeric micelle-type drug composition and method for the preparation thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
CN106659797A (zh) * 2014-05-29 2017-05-10 纪念斯隆-凯特琳癌症中心 纳米粒子药物结合物
CN106659797B (zh) * 2014-05-29 2021-04-27 纪念斯隆-凯特琳癌症中心 纳米粒子药物结合物
CN113082225A (zh) * 2014-05-29 2021-07-09 纪念斯隆-凯特琳癌症中心 纳米粒子药物结合物
CN114259573A (zh) * 2022-01-06 2022-04-01 中国人民解放军军事科学院军事医学研究院 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途
CN114259573B (zh) * 2022-01-06 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途
CN115382476A (zh) * 2022-07-26 2022-11-25 华东师范大学 一种超小粒径聚合物纳米颗粒的制备方法

Also Published As

Publication number Publication date
IN2012DN05099A (https=) 2015-10-09
JP2013514977A (ja) 2013-05-02
EP2512522A4 (en) 2013-09-25
EA201290506A1 (ru) 2013-03-29
EP2512522A2 (en) 2012-10-24
WO2011084620A3 (en) 2011-11-17
WO2011084620A2 (en) 2011-07-14
US20130017265A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
CN102791294A (zh) 用于多种药物递送的粒子
Khandare et al. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges
US8603532B2 (en) Nanostructures for drug delivery
US9931410B2 (en) Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
Jiang et al. Influencing selectivity to cancer cells with mixed nanoparticles prepared from albumin–polymer conjugates and block copolymers
Zhang et al. Drug delivery systems for differential release in combination therapy
US9649391B2 (en) Particles with multiple functionalized surface domains
Mignani et al. Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report
Wang et al. Advances of cancer therapy by nanotechnology
Alexis et al. New frontiers in nanotechnology for cancer treatment
Mozafari et al. Role of nanocarrier systems in cancer nanotherapy
US10092617B2 (en) Polymeric nanoparticles and a process of preparation thereof
Pearson et al. Dendritic nanoparticles: the next generation of nanocarriers?
CN108135917B (zh) 基于包含多糖-维生素缀合物的颗粒的药物制剂
Moradpour et al. Novel approaches for efficient delivery of tyrosine kinase inhibitors
US20220175688A1 (en) Polymeric nanoparticles
Sunoqrot et al. Synergistic interplay of medicinal chemistry and formulation strategies in nanotechnology-from drug discovery to nanocarrier design and development
Lakshmanan et al. Chitosan-based nanoparticles in cancer therapy
CA2946155A1 (en) Nanoparticles comprising docetaxel for treating cancers having a k-ras mutation
KR20210053881A (ko) 살리노마이신을 포함하는 폴리머 나노입자
KR20200090193A (ko) 보르테조밉을 포함하는 중합체 나노입자
Asfia et al. Polymeric nanoparticulates as efficient anticancer drugs delivery systems
Li et al. Recent advances in nanoparticles targeting TGF-β signaling for cancer treatment
Landesman-Milo et al. Targeting cancer using nanocarriers
Zhao et al. Macromolecular therapeutics: development and delivery engineering

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121121